A First Time In Human Study To Assess The Compound GSK615915
Status:
Completed
Trial end date:
2006-07-03
Target enrollment:
Participant gender:
Summary
GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's
future generation of Metered Dose Inhalers (MDIs). A surfactant in a MDI would provide a more
stable drug suspension, this in turn will produce a consistent dose of drug being delivered
with each puff.